At Abbott, we understand chronic pain is personal, and it can be difficult to find relief.
That’s why Abbott continues to develop new treatments for different kinds of pain, including complicated conditions that have not responded to treatment in the past.
Someone experiencing intense pain that started after an injury or a surgical procedure might have something called Complex Regional Pain Syndrome (CRPS I) or Causalgia (CRPS II). Proclaim™ DRG therapy can treat chronic pain associated with CRPS or causalgia of the lower body,1 including:
Proclaim™ DRG therapy is a novel neurostimulation technology that targets and relieves pain at the source. Traditional neurostimulation has been used safely for decades, but it doesn’t always work for people with CRPS I or causalgia (CRPS II).2
Proclaim™ DRG therapy is proven to provide superior* and long-term pain relief for people with CRPS I and causalgia (CRPS II).2
The Proclaim™ DRG Neurostimulation System utilizes recharge-free technology, relieving you from the time and hassles of recharging, unlike rechargeable neurostimulation systems that require frequent charging sessions or numerous office visits to maintain therapy. This means that you can get hassle-free pain relief with a battery that lasts 6.5 years at nominal settings** without ever needing to charge the system.
Everyone has clusters of nerve cells along their spine called dorsal root ganglion (DRG).
Researchers have found that certain groups of DRG nerves control pain signals from specific areas of the body – such as the pelvis, groin, hip, knee, ankle and foot – where people experience the pain.
By focusing electrical stimulation specifically on the DRG, we’re able to interrupt pain signals before they reach the spinal cord or brain, so you don’t feel pain in the same way. Interrupting these pain signals at the source allows the use of low-energy levels on a recharge-free platform and helps eliminate unnecessary stimulation throughout the body, unlike SCS neurostimulation systems.2
The result: With the Proclaim™ DRG Neurostimulation System, you can now have superior* pain relief without the hassles of recharging.
In this webinar, Dr. Ajay Antony and Dr. Kiran Patel discuss chronic pain and its management, Proclaim™ DRG therapy for CRPS I and causalgia of the lower extremities1 and steps to getting Proclaim™ DRG therapy.
PROCLAIM™ DRG THERAPY
TARGETED RELIEF. AT THE SOURCE.
Proclaim™ DRG therapy can be trialed before committing to another surgery.
DURING THE TRIAL, YOU CAN ASSESS WHETHER THE THERAPY:
Provides meaningful pain relief
Improves your ability to perform daily activities
Improves your sleeping habits
Take the first step and find a DRG doctor near you:
Request additional information about chronic pain and opt-in to begin your pain relief journey today.
Prior to using these devices, please review the User’s Guide for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. The system is intended to be used with leads and associated extensions that are compatible with the system.
Indications for Use:
US: Spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable* pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II.**
*Study subjects from the ACCURATE clinical study had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes and continued their pharmacologic therapy during the clinical study.
**Please note that in 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) reviewed diagnostic criteria and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex regional pain syndrome (CRPS) types I and II, respectively. CRPS II (causalgia) is defined as a painful condition arising from damage to a nerve. Nerve damage may result from traumatic or surgical nerve injury. Changes secondary to neuropathic pain seen in CRPS I (RSD) may be present, but are not a diagnostic requirement for CRPS II (causalgia).
International: Management of chronic intractable pain.
US: Patients who are unable to operate the system, who are poor surgical risks. Patients who have failed to receive effective pain relief during trial stimulation.
International: Patients who are unable to operate the system, are poor surgical risks, are pregnant, or under the age of 18.
Diathermy therapy, implanted cardiac systems or other active implantable devices, magnetic resonance imaging (MRI), computed tomography (CT), electrosurgery devices, ultrasonic scanning equipment, therapeutic radiation, explosive and flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery, equipment and vehicles, pediatric use, pregnancy, and case damage.
Unpleasant sensations, changes in stimulation, stimulation in unwanted places, lead or implant migration, epidural hemorrhage, hematoma, infection, spinal cord compression, or paralysis from placement of a lead in the epidural space, cerebrospinal fluid leakage, tissue damage or nerve damage, paralysis, weakness, clumsiness, numbness, sensory loss, or pain below the level of the implant, pain where needle was inserted or at the electrode site or at IPG site, seroma at implant site, headache, allergic or rejection response, battery failure and/or leakage. User’s Guide must be reviewed for detailed disclosure.
Caution: federal law (usa) restricts this device to sale, and use by or on the order of a physician.
*When compared to traditional tonic stimulation as studied by ACCURATE.
**Dual-lead system with one-year shelf life at 1600-ohms impedance and 24 hours of 20-Hz frequency, 300-μs pulse width, and 0.8-mA amplitude stimulation. Hassle-free means recharge-free.
1. Proclaim DRG Neurostimulation System Clinician’s Manual. Plano, TX. 2017.
2. Deer, TR, Levy, RM, Kramer, J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain 2017;158(4):669-681. ACCURATE IDE STUDY, St. Jude Medical. (n=152).